{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:59:34Z","timestamp":1768870774975,"version":"3.49.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.msard.2022.104059","type":"journal-article","created":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T12:47:15Z","timestamp":1658753235000},"page":"104059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3941-8020","authenticated-orcid":false,"given":"Thomas","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Kamath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saji K","family":"John","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Netravathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajesh B","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Raghavendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Neeharika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salil","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uday","family":"Murgod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Shivakumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi K","family":"Annadure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasli","family":"Ichaporia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anshu","family":"Rohatgi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sruthi S","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sireesha","family":"Yareeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bawani","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prabhjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umashankar","family":"Renukaradhya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Arulselvan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y Muralidhar","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nirmal","family":"Surya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.R.K.","family":"Sarma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raghunandan","family":"Nadig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saikanth","family":"Deepalam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.G.","family":"Sharath Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Satishchandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhim Sen","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gareth","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104059_bib0015","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/ana.24651","article-title":"Rituximab versus fingolimod after natalizumab in multiple sclerosis patients","volume":"79","author":"Alping","year":"2016","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104059_bib0007","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of initial disease-modifying therapy with later conversion to secondary progressive multiple sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.msard.2022.104059_bib0003","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1136\/jnnp-2019-322326","article-title":"Tysabri Observational Program (TOP) Investigators. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)","volume":"91","author":"Butzkueven","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2022.104059_bib0008","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases","volume":"9","author":"Clifford","year":"2010","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2022.104059_bib0017","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1212\/NXI.0000000000000388","article-title":"\u03b14-integrin receptor desaturation and disease activity return after natalizumab cessation","volume":"4","author":"Derfuss","year":"2017","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.104059_bib0005","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/PPA.S134865","article-title":"Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis","volume":"11","author":"Foley","year":"2017","journal-title":"Patient Prefer. Adherence"},{"key":"10.1016\/j.msard.2022.104059_bib0018","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2147\/PPA.S134865","article-title":"Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis","volume":"11","author":"Foley","year":"2017","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.msard.2022.104059_bib0011","series-title":"Presented at: 2020 American Academy of Neurology (AAN) Annual Meeting","article-title":"Updated Incidence of Natalizumab Associated Progressive Multifocal Leukoencephalopathy (PML) and its relationship with natalizumab exposure overTime","author":"GiovannoniG","year":"2020"},{"issue":"4","key":"10.1016\/j.msard.2022.104059_bib0006","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","article-title":"MSBase study group. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study","volume":"19","author":"He","year":"2020","journal-title":"Lancet Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.104059_bib0010","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.104059_bib0004","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40120-015-0038-9","article-title":"Natalizumab discontinuation and treatment strategies in patients with multiple sclerosis (MS): a retrospective study from two Italian MS centers","volume":"4","author":"Lo Re","year":"2015","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2022.104059_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102210","article-title":"Efficacy and safety of rituximab in multiple sclerosis: experience from a developing country","volume":"43","author":"Mathew","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2022.104059_bib0001","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis","volume":"348","author":"Miller","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104059_bib0014","doi-asserted-by":"crossref","DOI":"10.1177\/13524585221089890","article-title":"Low-dose rituximab should be used for treating MS in resource-limited settings: yes","author":"Piehl","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2022.104059_bib0002","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.104059_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/1756286419837809","article-title":"Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis","volume":"12","author":"Prosperini","year":"2019","journal-title":"Ther. Adv. Neurol. Dis."},{"issue":"4","key":"10.1016\/j.msard.2022.104059_bib0009","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.msard.2014.04.003","article-title":"Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients","volume":"3","author":"Sangalli","year":"2014","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.104059_bib0016","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.msard.2014.04.003","article-title":"Long-term management of natalizumab discontinuation in a large monocentric cohort of multiple sclerosis patients","volume":"3","author":"Sangalli","year":"2014","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:02:33Z","timestamp":1761901353000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":18,"alternative-id":["S2211034822005673"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104059","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A real world multi center study on efficacy and safety of natalizumab in Indian patients with multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104059"}}